Acadia Pharma Files 8-K on Financial Results and Exhibits
Ticker: ACAD · Form: 8-K · Filed: 2024-02-27T00:00:00.000Z
Sentiment: neutral
Topics: financial-reporting, 8-K, disclosure
Related Tickers: ACAD
TL;DR
**Acadia Pharma just filed an 8-K about their financials, but the specific details aren't in this snippet.**
AI Summary
Acadia Pharmaceuticals Inc. filed an 8-K on February 27, 2024, to report on its "Results of Operations and Financial Condition" and "Financial Statements and Exhibits." This routine filing indicates the company is providing an update on its financial performance, though specific figures are not detailed in this excerpt. The company's business address is 12830 El Camino Real, Suite 400, San Diego, California 92130.
Why It Matters
This filing signals that Acadia Pharmaceuticals is providing an update on its financial performance, which is crucial for investors to assess the company's health and future prospects. Without the actual financial data, its immediate impact is limited to the notification of the update.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial reporting, not an event that inherently carries high risk based on the provided text.
Key Players & Entities
- Acadia Pharmaceuticals Inc. (company) — Registrant
- Delaware (location) — State of Incorporation
- San Diego (location) — City of Principal Executive Offices
- February 27, 2024 (date) — Date of earliest event reported
FAQ
What is the exact name of the Registrant as specified in its charter?
The exact name of the Registrant is Acadia Pharmaceuticals Inc.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is February 27, 2024.
What items are reported under ITEM INFORMATION in this 8-K?
The items reported are "Results of Operations and Financial Condition" and "Financial Statements and Exhibits."
What is the business address of Acadia Pharmaceuticals Inc.?
The business address is 12830 El Camino Real, Suite 400, San Diego, California 92130.
What is the Registrant's telephone number?
The Registrant's telephone number is (858) 558-2871.
Filing Stats: 529 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-02-27 16:16:24
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ACAD The Nasdaq Stock Mar
Filing Documents
- acad-20240227.htm (8-K) — 39KB
- acad-ex99_1.htm (EX-99.1) — 218KB
- 0000950170-24-021169.txt ( ) — 382KB
- acad-20240227.xsd (EX-101.SCH) — 24KB
- acad-20240227_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 27, 2024, Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023. A copy of this press release is furnished herewith as Exhibit 99.1. Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated February 27, 2024. 104 Cover page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Acadia Pharmaceuticals Inc. Date: February 27, 2024 By: /s/ Jennifer J. Rhodes Jennifer J. Rhodes Executive Vice President, Chief Legal Officer